New rabies vaccine shows promise in large trial
NCT ID NCT03965962
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 20 times
Summary
This study tested a new rabies vaccine (VRVg-2) in 640 healthy adults to see if it works as well as two existing vaccines. Participants received the vaccine along with rabies immune globulin, mimicking what happens after a rabies exposure. The main goal was to check if the new vaccine triggers enough antibodies by day 28. The trial is complete and aims to offer another safe option for rabies prevention.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RABIES (HEALTHY VOLUNTEERS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number 2500001
Rennes, 35000, France
-
Investigational Site Number 2500002
Gières, 38610, France
Conditions
Explore the condition pages connected to this study.